8.1 Canadian Federal Legislation: Food and Drugs Act & CDSA
Key Takeaways
The Food and Drugs Act and Food and Drug Regulations set national standards for drug safety, efficacy, quality, manufacturing, packaging and labelling across Canada.
The Prescription Drug List (PDL) replaced the former Schedule F in December 2013 and lists the medicinal ingredients that require a prescription for human or veterinary use.
An 8-digit Drug Identification Number (DIN) shows that a drug product is authorized for sale in Canada; natural health products carry an 8-digit NPN or a DIN-HM.
Section 3 of the Food and Drugs Act bans advertising to the public any product as a treatment, preventative or cure for a Schedule A disease, and prescription drug ads are limited to name, price and quantity.
A pharmacist must send Health Canada a written report of any loss or theft of a controlled substance within 10 days after becoming aware of it; thefts are also reported to police.
Canadian Federal Legislation: Food and Drugs Act & CDSA
Exam Tip: On the PEBC Qualifying Examination, candidates must thoroughly understand the division between federal and provincial authority. Federal legislation governs the product (safety, efficacy, quality, manufacturing, import/export, and criminal scheduling), whereas provincial legislation governs the practice (licensing of pharmacies, registration of professionals, and operational scopes). Candidates are frequently tested on identifying Health Canada packaging symbols, advertising limits, and strict statutory loss/theft reporting deadlines.
The Canadian Federal Legislative Framework
In Canada, the authority of the federal government over medications and controlled substances is grounded in the constitutional power over criminal law and national trade. The primary federal health department is Health Canada (Santé Canada), headed by the federal Minister of Health. Within Health Canada, specialized branches—such as the Health Products and Food Branch (HPFB) and the Office of Controlled Substances (OCS)—oversee the regulatory lifecycle of pharmaceuticals, biological products, medical devices, natural health products, and controlled substances.
Two central federal statutes establish the legal backbone of pharmacy inventory and drug safety across all provinces and territories:
- The Food and Drugs Act (FDA) and its subordinate regulations, primarily the Food and Drug Regulations (FDR) and the Natural Health Products Regulations (NHPR).
- The Controlled Drugs and Substances Act (CDSA) and its regulations. Since October 1, 2026, pharmacy activities with narcotics, controlled drugs and targeted substances are governed by the consolidated Controlled Substances Regulations (CSR), which replaced the Narcotic Control Regulations (NCR), the Benzodiazepines and Other Targeted Substances Regulations (BOTSR), and Parts G and J of the FDR.
The Food and Drugs Act (FDA) & Food and Drug Regulations (FDR)
The Food and Drugs Act is an act of the Parliament of Canada regarding the production, import, export, transport across provinces, and sale of food, drugs, contraceptive devices, and cosmetics. Its core purpose is to protect the Canadian public against health hazards, fraud, adulteration, and misleading claims in the sale and use of foods, drugs, cosmetics, and medical devices.
The Prescription Drug List (PDL) and the Schedule F Legacy
Historically, prescription-only medications in Canada were listed under Schedule F of the Food and Drug Regulations. In December 2013, Health Canada officially replaced Schedule F with the Prescription Drug List (PDL).
- The PDL is an administrative list maintained by Health Canada under the Food and Drugs Act and incorporated by reference into the Food and Drug Regulations, so it can be updated without amending the regulations.
- It contains medicinal ingredients that require a prescription for human or veterinary use when sold in Canada.
- The PDL is divided into two separate sections:
- Human Use List: Active ingredients intended for administration to humans requiring a prescription (e.g., atorvastatin, amoxicillin, metformin, lisinopril).
- Veterinary Use List: Active ingredients intended for administration to animals requiring a veterinary prescription.
- Crucial Distinction: Controlled substances, narcotics, and targeted substances are governed separately under the CDSA and are not listed on the PDL.
Drug Identification Numbers (DIN)
Under Section C.01.014 of the Food and Drug Regulations, no manufacturer may sell a drug in dosage form in Canada unless a Drug Identification Number (DIN) has been issued by Health Canada:
- A DIN is an 8-digit numerical code assigned to each approved prescription, non-prescription (OTC), or biological drug product.
- A DIN shows that Health Canada has authorized the product for sale in Canada. For new drugs, including most generics, that authorization follows a Notice of Compliance (NOC) issued after a review of safety, efficacy and quality data.
- Any change in the active ingredient, strength, dosage form, route of administration, or brand name necessitates an application for a distinct, separate DIN.
Natural Health Products (NHPs): NPN and DIN-HM
Regulated under the Natural Health Products Regulations (NHPR), natural health products include herbal remedies, vitamins, mineral supplements, essential fatty acids, probiotics, traditional medicines (e.g., traditional Chinese medicines), and homeopathic preparations:
- Natural Product Number (NPN): An 8-digit numeric code appearing on the front label of natural health products, confirming that Health Canada has evaluated and approved the product for safety, efficacy, and Good Manufacturing Practices (GMP).
- Homeopathic Medicine Number (DIN-HM): An 8-digit numeric code specific to homeopathic preparations authorized under the NHPR.
- Natural health products must not contain substances listed on the Prescription Drug List (PDL) or schedules of the CDSA.
Packaging and Labelling Requirements under the FDR
Health Canada enforces strict packaging and labelling standards to guarantee that both healthcare professionals and patients can readily identify medications, prepare accurate doses, and handle products safely.
Inner and Outer Label Specifications
The FDR defines an inner label as the label on or affixed to an immediate container (e.g., stock bottle, vial, blister strip), and an outer label as the label on or affixed to the outside packaging (e.g., cardboard carton, box).
| Mandatory Label Element | Inner Container Label | Outer Packaging Carton |
|---|---|---|
| Brand / Proprietary Name | Required | Required |
| Proper / Generic Chemical Name | Required (immediately adjacent to brand name) | Required (immediately adjacent to brand name) |
| Strength & Dosage Form | Required (e.g., 20 mg tablet, 50 mg/mL) | Required |
| Drug Identification Number (DIN) | Required (8-digit code, e.g., DIN 01234567) | Required |
| Manufacturer / Distributor Name & Address | Required (at least city and country) | Required (full legal address) |
| Lot / Batch Number | Required (preceded by "Lot", "(L)", or "Batch") | Required |
| Expiration Date | Required (year and month, e.g., 2027-AL) | Required |
| Net Quantity / Contents | Required if space permits | Required (e.g., 100 Tablets, 500 mL) |
| Storage Conditions | Required (e.g., Store at 15°C–30°C; Protect from light) | Required |
| Bilingual Labelling | French and English required | French and English required |
Federal Warning Symbols and Scheduling Indicators
The front label of a pharmaceutical product must display distinct statutory symbols in the upper left quadrant of the main display panel to communicate its legal status:
- Pr Symbol: Indicates a prescription drug listed on the federal Prescription Drug List (PDL).
- C Symbol: Indicates a controlled drug (e.g., methylphenidate, lisdexamfetamine, phenobarbital, testosterone). Controlled drugs were in Part G of the FDR until September 30, 2026, and are now in Schedule 2 of the CSR.
- N Symbol: Indicates a narcotic (e.g., morphine, oxycodone, codeine, tramadol, nabilone), formerly under the NCR and now in Schedule 1 of the CSR.
- T/C Symbol: Indicates a targeted substance (e.g., lorazepam, diazepam, zolpidem). Zopiclone is a prescription drug but not a controlled substance in Canada.
Canadian Advertising Restrictions: Direct-to-Consumer Rules
Direct-to-consumer advertising (DTCA) of prescription drugs in Canada is subject to some of the strictest legal restrictions in the developed world, contrasting sharply with United States practices.
Section 3 Prohibitions (Schedule A Diseases)
Under Section 3 of the Food and Drugs Act, no person shall advertise any food, drug, cosmetic, or device to the general public as a treatment, preventative, or cure for any disease, disorder, or abnormal physical state listed in Schedule A.
- Schedule A lists serious conditions such as cancer, diabetes, hypertension, asthma, congestive heart failure, depression, convulsions and sexually transmitted diseases.
- The rationale is to prevent vulnerable patients from self-diagnosing or self-medicating potentially fatal conditions without medical supervision.
Permissible Prescription Drug Advertising Categories in Canada
Health Canada's Policy on The Distinction Between Advertising and Other Activities allows only two limited formats for public communication regarding prescription medications:
- Reminder Advertisements:
- May mention the brand name, price, and quantity of a prescription drug.
- Strict Prohibition: Must NOT mention the disease state, therapeutic claims, indications, symptoms treated, or dosage instructions.
- Help-Seeking / Disease-Awareness Campaigns:
- May discuss a medical condition, symptoms, and encourage patients to talk to their healthcare provider.
- Strict Prohibition: Must NOT mention any specific brand name, product name, or manufacturer's proprietary molecule.
Critical Legal Rule: A Canadian advertisement that connects a specific prescription brand name with a therapeutic claim or medical condition directed to the general public is illegal under the Food and Drugs Act.
Controlled Drugs and Substances Act (CDSA): Structure & Schedules
Enacted in 1996, the Controlled Drugs and Substances Act (CDSA) repealed the former Narcotic Control Act and Parts III and IV of the Food and Drugs Act, consolidating Canada's control framework for substances with recognized potential for abuse, physical dependence, psychological addiction, or societal harm.
Legislative Purpose
The CDSA provides a dual-track framework: it establishes strict control mechanisms to enable the legitimate medical, scientific, and industrial use of scheduled substances while creating severe criminal law prohibitions against illicit manufacturing, importation, distribution, and diversion.
Overview of CDSA Schedules
| CDSA Schedule | Primary Drug Classes Included | Key Representative Substances |
|---|---|---|
| Schedule I | Opioids and related substances, coca, amphetamines and methamphetamine, and others | Morphine, oxycodone, hydromorphone, fentanyl, methadone, tramadol, cocaine, heroin, ketamine, amphetamine, methamphetamine |
| Schedule II | Synthetic cannabinoid receptor agonists (cannabis itself moved to the Cannabis Act in 2018) | Synthetic cannabinoids |
| Schedule III | Stimulants and hallucinogens not in Schedule I | Methylphenidate, lysergic acid diethylamide (LSD), mescaline, psilocybin |
| Schedule IV | Sedative-hypnotics, anxiolytics and anabolic steroids | Benzodiazepines (lorazepam, diazepam), barbiturates, anabolic steroids (testosterone) |
| Schedule V | Temporary listings: new psychoactive substances and precursors controlled for a limited period while permanent scheduling is considered | Substances listed with a defined period |
| Schedule VI | Precursors used in illicit drug production | Class A: ephedrine, pseudoephedrine, red phosphorus; Class B: solvents such as acetone and toluene |
Amphetamines and methamphetamine moved from Schedule III to Schedule I in 2012. The old cannabis sentencing Schedules VII and VIII were repealed when the Cannabis Act came into force.
Core Criminal Offenses under the CDSA
- Section 4 (Unlawful Possession): Prohibits obtaining or possessing any substance in Schedules I, II, or III without lawful authorization (e.g., a valid prescription or Section 56 exemption).
- Section 5 (Trafficking and Possession for the Purpose of Trafficking): Prohibits selling, administering, giving, transferring, transporting, or distributing a scheduled substance without authorization.
- Section 6 (Importing and Exporting): Strictly forbids transporting controlled substances across international borders without an explicit federal permit.
- Section 7 (Production): Prohibits manufacturing, synthesizing, or cultivating scheduled substances without a federal dealer's licence.
Health Canada Enforcement, Office of Controlled Substances & Loss/Theft Reporting
The Office of Controlled Substances (OCS) within Health Canada administers federal controlled substance regulations, issues Dealer's Licences to pharmaceutical manufacturers and wholesalers, conducts facility audits, and grants ministerial exemptions under Section 56 of the CDSA (such as authorizing Supervised Consumption Sites or specialized scientific research).
Mandatory Loss and Theft Reporting
Discovery of Loss or Theft (technician notifies the pharmacist immediately)
│
▼
Theft (break-in, robbery, forged Rx that was filled): report to police
│
▼
Investigate and document (counts, records, possible explanation)
│
▼
Pharmacist submits a written report to Health Canada
(E-Services Portal or Loss or Theft Report Form)
⏰ WITHIN 10 DAYS AFTER BECOMING AWARE
- Statutory Timeline: Under the CSR (s. 109), a pharmacist who becomes aware of a loss or theft of a controlled substance, or is told about one by an agent or employee, must give the Minister of Health a written report within 10 days. The legacy rules had the same 10-day deadline (NCR s. 42, FDR G.03.013, BOTSR s. 72).
- Technician Duty: A pharmacy technician who discovers a loss or theft must notify the pharmacist immediately.
- Reporting Mechanism: Reports go through Health Canada's E-Services Portal or its Loss or Theft Report Form, following Health Canada's guidance document on reporting loss or theft of controlled substances (CS-GD-005).
- Police: Thefts such as robberies and break-ins are reported to the police. Keep the police report details, because Health Canada's report asks about police involvement.
- What Must Be Reported?
- Theft: any removal without legitimate consent, including a forged prescription that was filled in whole or in part. An attempted forgery where nothing was dispensed is not reported to Health Canada.
- Loss: a physical disappearance that cannot be explained when discovered (for example, an unexplained shortfall in a perpetual inventory count, or stock missing from a delivery).
- Internal diversion discovered through audits or surveillance is a theft.
Explained Losses vs. Reportable Losses
- Witnessed breakage or spillage: If an oxycodone tablet is dropped down a drain in front of a colleague, or a bottle of methadone solution breaks, the fate of the drug is known. Document it right away (what, how much, how, who witnessed it) and adjust the inventory record according to the pharmacy's procedures.
- If the quantity cannot be reconciled or the explanation is doubtful, treat it as an unexplained loss and report it within 10 days.
On October 12, 2026, a community pharmacy technician finds during a count that an unopened bottle of 100 oxycodone 20 mg tablets is missing from the safe. Security footage shows that someone forced the rear dispensary door overnight. What is the required reporting procedure?
The technician tells the pharmacist immediately; the break-in is reported to police, and the pharmacist sends Health Canada a written loss or theft report within 10 days after becoming aware of the theft.
Record the loss in the internal discrepancy log and report it at the next provincial college inspection.
Phone Health Canada within 24 hours, and file a written police report within 30 days.
Adjust the perpetual inventory to zero and ask the manufacturer for a replacement credit; no report is needed because the stock was stolen, not lost.
A pharmaceutical sales representative visits an independent community pharmacy and asks the pharmacy technician to display an educational countertop poster in the public waiting area. The poster prominently displays the brand name of a newly launched biologic prescription drug for plaque psoriasis, features patient testimonials claiming complete remission, and provides a QR code for patients to ask their doctor for a prescription. Under the Food and Drugs Act and Health Canada advertising guidelines, is this promotional material legally permissible?
Yes, because direct-to-consumer advertising of prescription drugs is fully permitted in Canada as long as clinical trial efficacy data is cited.
No, because Canadian federal regulations prohibit direct-to-consumer advertising that connects a specific prescription brand name with therapeutic claims or indications for use.
Yes, provided the manufacturer has obtained an authorized Drug Identification Number (DIN) and registered the poster with the provincial pharmacy college.
No, because advertising prescription medications is only permitted on broadcast television and prohibited in physical community pharmacy premises.
A pharmacy technician is unpacking a wholesaler order and verifying incoming stock against the invoice. One of the products is an herbal sleep supplement containing valerian root and chamomile, labeled with the identifier 'NPN 80012345'. Another product is a topical eczema cream containing hydrocortisone 1%, labeled with 'DIN 02245678'. How do these product identifiers differ under Canadian federal health legislation?
Both identifiers are issued under the Controlled Drugs and Substances Act, but the NPN designates a lower-risk controlled schedule.
The DIN indicates a food-grade cosmetic requiring no safety review, while the NPN indicates a high-potency prescription drug authorized by the province.
The NPN is issued under the Natural Health Products Regulations confirming safety, efficacy, and quality for natural ingredients, while the DIN is issued under the Food and Drug Regulations for pharmaceutical drugs.
The NPN indicates an unapproved extemporaneous compound prepared without quality controls, while the DIN indicates an approved veterinary medication.
Sections you finish are checked off in the contents.